Alterations in the Course of Inflammatory Bowel Disease Following Liver Transplantation: A Systematic Review and Meta-analysis

被引:2
作者
Safarpour, Ali Reza [1 ]
Shojaei-Zarghani, Sara [1 ]
Mehrabi, Manoosh [2 ]
Keshtkar, Abbas Ali [3 ]
Oroojan, Ali Akbar [4 ]
Sivandzadeh, Gholam Reza [1 ]
机构
[1] Shiraz Univ Med Sci, Gastroenterohepatol Res Ctr, Shiraz, Iran
[2] Shiraz Univ Med Sci, Virtual Sch, Dept E Learning, Shiraz, Iran
[3] Univ Tehran Med Sci, Sch Publ Hlth, Dept Hlth Sci Educ Dev, Tehran, Iran
[4] Dezful Univ Med Sci, Dept Physiol, Fac Med, Dezful, Iran
关键词
inflammatory bowel disease; colitis; Crohn's disease; liver transplantation; PRIMARY SCLEROSING CHOLANGITIS; ULCERATIVE-COLITIS; CLINICAL-COURSE; IMMUNOSUPPRESSION; RISK;
D O I
10.1093/ibd/izac132
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Lay Summary Our meta-analysis revealed that inflammatory bowel disease (IBD) activity remained "unchanged" (or "improved/unchanged") in most IBD patients following liver transplantation. IBD type, age, and follow-up length could influence the IBD course after liver transplantation. Background This study aimed to systematically review and pool data regarding the alterations in the clinical course of inflammatory bowel disease (IBD) following liver transplantation (LT). Methods Relevant prospective and retrospective observational studies were identified by searching databases and gray literature through December 2020. Random-effects models were used to calculate the pooled frequency of IBD patients with disease course alterations ("improved," "unchanged," or "aggravated") after LT and the corresponding 95% confidence intervals (CIs). Results Twenty-five studies met our inclusion criteria, reporting the outcomes in 2 or 3 categories. In the analysis of studies with 3-category outcomes (n = 13), the pooled frequencies of patients with improved, unchanged, or aggravated IBD course after LT were 29.4% (95% CI, 16.9% to 41.9%), 51.4% (95% CI, 45.5% to 57.3%), and 25.2% (95% CI, 15.6% to 34.8%), respectively. Subgroup analyses revealed that patients with ulcerative colitis (UC), younger age at LT, or shorter duration of follow-up were more likely to have an improved disease course. Moreover, higher IBD exacerbation estimates were observed in studies with a low risk of bias. In the analysis of studies with 2-category outcomes (n = 12), the pooled frequencies of patients with improved/unchanged or aggravated IBD course were 73.6% (95% CI, 62.2% to 85.0%) and 24.1% (95% CI, 15.1% to 33.2%), respectively. The cumulative incidence of an exacerbated IBD course following LT was 0.22 (95% CI, 0.16-0.29; P < .001). Conclusion We conclude that IBD activity remains unchanged (or improved/unchanged) in most IBD patients following LT. Furthermore, IBD type, age, and follow-up length can influence the IBD course after LT.
引用
收藏
页码:973 / 985
页数:13
相关论文
共 47 条
[1]   The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [J].
Alatab, Sudabeh ;
Sepanlou, Sadaf G. ;
Ikuta, Kevin ;
Vahedi, Homayoon ;
Bisignano, Catherine ;
Safiri, Saeid ;
Sadeghi, Anahita ;
Nixon, Molly R. ;
Abdoli, Amir ;
Abolhassani, Hassan ;
Alipour, Vahid ;
Almadi, Majid A. H. ;
Almasi-Hashiani, Amir ;
Anushiravani, Amir ;
Arabloo, Jalal ;
Atique, Suleman ;
Awasthi, Ashish ;
Badawi, Alaa ;
Baig, Atif A. A. ;
Bhala, Neeraj ;
Bijani, Ali ;
Biondi, Antonio ;
Borzi, Antonio M. ;
Burke, Kristin E. ;
Carvalho, Felix ;
Daryani, Ahmad ;
Dubey, Manisha ;
Eftekhari, Aziz ;
Fernandes, Eduarda ;
Fernandes, Joao C. ;
Fischer, Florian ;
Haj-Mirzaian, Arvin ;
Haj-Mirzaian, Arya ;
Hasanzadeh, Amir ;
Hashemian, Maryam ;
Hay, Simon, I ;
Hoang, Chi L. ;
Househ, Mowafa ;
Ilesanmi, Olayinka S. ;
Balalami, Nader Jafari ;
James, Spencer L. ;
Kengne, Andre P. ;
Malekzadeh, Masoud M. ;
Merat, Shahin ;
Meretoja, Tuomo J. ;
Mestrovic, Tomislav ;
Mirrakhimov, Erkin M. ;
Mirzaei, Hamed ;
Mohammad, Karzan A. ;
Mokdad, Ali H. .
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2020, 5 (01) :17-30
[2]   Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series [J].
Altwegg, Romain ;
Combes, Roman ;
Laharie, David ;
De Ledinghen, Victor ;
Radenne, Sylvie ;
Conti, Filomena ;
Chazouilleres, Olivier ;
Duvoux, Christophe ;
Dumortier, Jerome ;
Leroy, Vincent ;
Treton, Xavier ;
Durand, Francois ;
Dharancy, Sebastien ;
Nachury, Maria ;
Goutorbe, Felix ;
Lamblin, Geraldine ;
Boivineau, Lucile ;
Peyrin-Biroulet, Laurent ;
Pageaux, Georges-Philippe .
DIGESTIVE AND LIVER DISEASE, 2018, 50 (07) :668-674
[3]   Emerging pharmacologic therapies for primary sclerosing cholangitis [J].
Cheung, Angela C. ;
Lazaridis, Konstantinos N. ;
LaRusso, Nicholas F. ;
Gores, Gregory J. .
CURRENT OPINION IN GASTROENTEROLOGY, 2017, 33 (03) :149-157
[4]   Combined HLA-DR and -DQ disparity is associated with a stable course of ulcerative colitis after liver transplantation for primary sclerosing cholangitis [J].
Cholongitas, Evangelos ;
Papatheodoridis, George V. ;
Zappoli, Paolo ;
Giannakopoulos, Athanasios ;
Patch, David ;
Marelli, Laura ;
Shusang, Vibhakorn ;
Kalambokis, George ;
Shirling, Graham ;
Rolando, Nancy ;
Burroughs, A. K. .
LIVER TRANSPLANTATION, 2007, 13 (04) :552-557
[5]  
Drastich P., 2013, GASTROENTEROLOGY, V144, pS
[6]   Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis [J].
Dvorchik, I ;
Subotin, M ;
Demetris, AJ ;
Fung, JJ ;
Starzl, TE ;
Wieand, S ;
Abu-Elmagd, KM .
HEPATOLOGY, 2002, 35 (02) :380-384
[7]   Clinical Course of Ulcerative Colitis After Liver Transplantation in Patients with Concomitant Primary Sclerosing Cholangitis and Ulcerative Colitis [J].
Fattahi, Mohammad Reza ;
Malek-Hosseini, Seyyed Ali ;
Sivandzadeh, Gholam Reza ;
Safarpour, Ali Reza ;
Lankarani, Kamran Bagheri ;
Taghavi, Ali Reza ;
Ejtehadi, Fardad .
INFLAMMATORY BOWEL DISEASES, 2017, 23 (07) :1160-1167
[8]   ULCERATIVE-COLITIS DISEASE-ACTIVITY AS SUBJECTIVELY ASSESSED BY PATIENT-COMPLETED QUESTIONNAIRES FOLLOWING ORTHOTOPIC LIVER-TRANSPLANTATION FOR SCLEROSING CHOLANGITIS [J].
GAVALER, JS ;
DELEMOS, B ;
BELLE, SH ;
HEYL, AE ;
TARTER, RE ;
STARZL, TE ;
GAVALER, C ;
VANTHIEL, DH .
DIGESTIVE DISEASES AND SCIENCES, 1991, 36 (03) :321-328
[9]   Activity of Ulcerative Colitis Before and After Liver Transplantation in Primary Sclerosing Cholangitis: The Hungarian Experience [J].
Gelley, F. ;
Miheller, P. ;
Peter, A. ;
Telkes, G. ;
Nemes, B. .
TRANSPLANTATION PROCEEDINGS, 2012, 44 (07) :2164-2165
[10]  
Gochanour Eric, 2020, Clin Liver Dis (Hoboken), V15, P125, DOI 10.1002/cld.902